CERUS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 USD | +0.59% |
|
+1.79% | -20.83% |
| Sales 2024 * | 179M 14.31B | Sales 2025 * | 203M 16.24B | Capitalization | 316M 25.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -1.6B | Net income 2025 * | -9M -720M | EV / Sales 2024 * | 1.77 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.56 x |
| P/E ratio 2024 * |
-15.5
x | P/E ratio 2025 * |
-34.2
x | Employees | 631 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cerus Corporation
More press releases
More news
| 1 day | +0.59% | ||
| 1 week | +1.79% | ||
| Current month | -9.52% | ||
| 1 month | -1.72% | ||
| 3 months | -8.56% | ||
| 6 months | +31.54% | ||
| Current year | -20.83% |
1 week
1.61
1.79
1 month
1.611.99
Current year
1.592.59
1 year
1.213.08
3 years
1.218.06
5 years
1.218.87
10 years
1.218.87
| Managers | Title | Age | Since |
|---|---|---|---|
Laurence Corash
FOU | Founder | 80 | 18/09/91 |
Obi Greenman
CEO | Chief Executive Officer | 57 | 31/12/94 |
Kevin Green
DFI | Director of Finance/CFO | 52 | 31/12/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jami Nachtsheim
BRD | Director/Board Member | 65 | 03/03/19 |
Obi Greenman
CEO | Chief Executive Officer | 57 | 31/12/94 |
Laurence Corash
FOU | Founder | 80 | 18/09/91 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.60% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.71 | +0.59% | 387,036 |
| 25/04/24 | 1.7 | +2.41% | 951,750 |
| 24/04/24 | 1.66 | -1.19% | 590,027 |
| 23/04/24 | 1.68 | -0.59% | 781,359 |
| 22/04/24 | 1.69 | +0.60% | 824,401 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.71
USD
Average target price
4.2
USD
Spread / Average Target
+145.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.83% | 316M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- CERS Stock
